Life Science Market Report 2026

The life science market size has grown rapidly in recent years. It will grow from $109.53 billion in 2025 to $123.41 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to growth in pharmaceutical r&d investments, expansion of biotechnology companies, adoption of laboratory automation, increasing demand for diagnostics, rising prevalence of chronic and rare diseases.

The life science market size is expected to see rapid growth in the next few years. It will grow to $200.59 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to advancements in precision medicine, growth in digital health solutions, integration of ai and big data analytics in research, increasing collaborations between academic and commercial research institutions, expansion of global clinical trials. Major trends in the forecast period include advanced drug discovery platforms, integrated clinical trial management, high-throughput laboratory automation, regulatory compliance and consulting services, bioinformatics and data analytics.

The increasing prevalence of chronic diseases is expected to drive the growth of the life science market going forward. Chronic diseases refer to long-term conditions that typically progress slowly and require continuous management rather than short-term care. The prevalence of chronic diseases is rising due to unhealthy lifestyle patterns such as poor nutrition, physical inactivity, and increasing obesity levels. The life science sector addresses chronic diseases by enabling the development of new therapies, diagnostics, and biologics that enhance long-term disease management and patient outcomes. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, 76.4% of US adults, representing 194 million people, reported one or more chronic conditions, including 59.5%, 78.4%, and 93% among young, midlife, and older adults, respectively. Therefore, the increasing prevalence of chronic diseases is driving the growth of the life science market.

Leading companies in the life science market are focusing on developing innovative products, such as patented peptide-based functional ingredients, to provide scientifically validated support for glucose regulation and metabolic health. Peptide-based functional ingredients are bioactive, short-chain amino acid compounds designed to interact with specific metabolic pathways to deliver targeted health benefits. For example, in December 2025, Greenyn Biotechnology Co. Ltd., a Taiwan-based provider of proprietary biotechnology-driven functional ingredients and health supplement solutions, launched Insumate mcIRBP-19 Bitter Melon Peptide, a bioactive peptide designed to support metabolic health in dietary supplement applications. The product features a uniquely identified bitter melon-derived peptide that mimics insulin receptor binding activity, supporting blood glucose control. It is produced using a low-temperature supercritical extraction process to preserve peptide bioactivity and consistency. Insumate mcIRBP-19 is backed by clinical validation and international certifications, positioning it as a next-generation, evidence-based nutraceutical ingredient targeting the rapidly growing metabolic health and diabetes-support segment.

In October 2025, MJH Life Sciences, a US-based healthcare information and analytics company, acquired BPD Healthcare for an undisclosed amount. With this acquisition, MJH Life Sciences broadened its medical education, healthcare communications, and marketing capabilities to better serve pharmaceutical, life sciences, and healthcare professional audiences. BPD Healthcare is a US-based company focused on healthcare communications and strategic medical marketing services.

Major companies operating in the life science market are Johnson & Johnson, Roche Holding AG, Pfizer Inc., AbbVie Inc., AstraZeneca plc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi S.A., Abbott Laboratories, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Novo Nordisk A/S, Amgen Inc., Eli Lily and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Astellas Pharma Inc., Biogen Inc., bioMérieux SA, Sartorius AG.

Tariffs have impacted the life science market by increasing costs for imported laboratory instruments, reagents, analytical tools, and biotechnology products. The effect is most significant on life science tools and medical device segments, particularly in regions such as Europe and Asia-Pacific that rely on foreign manufacturing. Positive impacts include incentivizing local manufacturing and promoting adoption of domestic digital health solutions and research software, which can reduce dependency on imports and stimulate regional innovation.

Life science refers to the broad field of science that studies living organisms and biological processes, including disciplines such as biology, genetics, microbiology, biochemistry, and biotechnology. It focuses on understanding the structure, function, growth, and interaction of living systems at the molecular, cellular, and organism levels. It helps to advance knowledge that supports healthcare, agriculture, environmental sustainability, and the development of medical and biotechnological innovations.

The primary types of life science include biotechnology, pharmaceuticals, medical devices, life science tools, and digital health solutions. Biotechnology involves the application of living systems and organisms to develop or manufacture products for healthcare, research, and industrial purposes. These solutions cover therapeutic areas such as oncology, cardiology, neurology, immunology, rare diseases, and other therapeutic areas. The main applications include drug discovery and development, diagnostics, therapeutics, clinical trials, and research and development. These solutions are adopted by end users such as pharmaceutical companies, biotechnology companies, academic and research institutions, and hospitals and clinics.

The life science market consists of revenues earned by entities by providing services such as research and development services, clinical trial management, laboratory testing and analysis, regulatory and compliance consulting, and bioinformatics support. The market value includes the value of related goods sold by the service provider or included within the service offering. The life science market also includes sales of laboratory instruments, analytical equipment, reagents and consumables, biotechnology products, diagnostic kits, and research tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The life science market research report is one of a series of new reports that provides life science market statistics, including life science industry global market size, regional shares, competitors with a life science market share, detailed life science market segments, market trends and opportunities, and any further data you may need to thrive in the life science industry. This life science market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.